SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): Discovery of antagonist SB-568849
摘要:
We report here the discovery of a class of MCH R1 ligands based on a biphenyl carboxamide template. A docked-in model is presented indicating key interactions in the putative binding site of the receptor. Parallel high throughput synthetic techniques were utilised to allow rapid exploration of the structure-activity relationship around this template, leading to compound SB-568849 which possessed good receptor affinity and selectivity. This compound proved to be an antagonist with stability in vivo, an acceptable brain-blood ratio and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.
Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents
申请人:SCHERING AKTIENGESELLSCHAFT
公开号:EP0332570A2
公开(公告)日:1989-09-13
Novel N-[4-aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents, especially as antiarrhythmic agents are described. Pharmaceutical formulations containing such compounds are also discussed.
Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as
申请人:Schering A.G.
公开号:US04906634A1
公开(公告)日:1990-03-06
Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents, especially as antiarrhythmic agents are described. Pharmaceutical formulations containing such compounds are also discussed.
SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): Discovery of antagonist SB-568849
作者:David R. Witty、John H. Bateson、Guillaume J. Hervieu、Phillip Jeffrey、Christopher N. Johnson、Alison I. Muir、Peter J. O’Hanlon、Geoffrey Stemp、Alex J. Stevens、Kevin M. Thewlis、Shelagh Wilson、Kim Y. Winborn
DOI:10.1016/j.bmcl.2006.06.056
日期:2006.9
We report here the discovery of a class of MCH R1 ligands based on a biphenyl carboxamide template. A docked-in model is presented indicating key interactions in the putative binding site of the receptor. Parallel high throughput synthetic techniques were utilised to allow rapid exploration of the structure-activity relationship around this template, leading to compound SB-568849 which possessed good receptor affinity and selectivity. This compound proved to be an antagonist with stability in vivo, an acceptable brain-blood ratio and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.